Blood Plasma Derivatives Market Report 2025

The blood plasma derivatives market size has grown strongly in recent years. It will grow from $51.81 billion in 2024 to $56.24 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increased prevalence of hemophilia and bleeding disorders, growth in geriatric population, increased awareness and diagnosis, rise in surgical procedures, global blood transfusion services.

The blood plasma derivatives market size is expected to see strong growth in the next few years. It will grow to $80.42 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to emergence of rare diseases therapies, growth in chronic diseases, increasing healthcare expenditure, patient-centric treatment approaches, growing healthcare infrastructure. Major trends in the forecast period include advancements in fractionation technologies, patient-centric approaches, collaborations and partnerships, expanding applications in neurology, technological innovations in plasma fractionation.

The rising incidence of immunodeficiency disorders is anticipated to drive the growth of the blood plasma derivatives market. Immunodeficiency disorders are conditions that either fully or partially weaken the immune system. Blood plasma derivatives are utilized in the treatment of various medical conditions, including immune deficiency disorders. Plasma, which is composed of proteins and salts, contains over 100 different proteins, with immunoglobulins being particularly important for treating primary immunodeficiencies. Factors like poor nutrition or malnutrition can result in macro- and micronutrient deficiencies, leading to immunodeficiency. For example, in March 2022, the Allergy, Asthma & Clinical Immunology reported that the most prevalent condition was Common Variable Immunodeficiency (CVID), affecting 16.6% of individuals in the US, 12.9% internationally, and 13.9% globally. Therefore, the increasing prevalence of immune deficiency disorders is contributing to the growth of the blood plasma derivatives market.

The rise in trauma and accident cases is expected to further accelerate the growth of the blood plasma derivatives market. Trauma and accident cases involve situations where individuals suffer physical injuries or harm due to unexpected incidents. Blood plasma derivatives are employed in these scenarios to replace clotting factors, treat hemorrhagic shock, assist in hemostasis and coagulation control, provide fluid replacement, support wound healing, and manage edema while maintaining fluid balance. For instance, in April 2024, the National Highway Traffic Safety Administration, a US government agency, reported that in 2022, 3,308 people were killed, and approximately 289,310 were injured in crashes involving distracted drivers. Thus, the increasing incidence of trauma and accident cases is fueling the growth of the blood plasma derivatives market.

The projected increase in the prevalence of hemophilia is set to be a significant driver propelling the growth of the blood plasma derivatives market. Hemophilia, a hereditary bleeding disorder, hinders proper blood clotting, leading to both spontaneous bleeding and bleeding following injury or surgical procedures. Individuals experiencing hemostasis-related issues, whether hereditary or acquired, often benefit from blood plasma-derived products or medications to effectively manage hemostasis. Treatments for conditions such as hemophilia A, von Willebrand disease, and hemophilia B involve the use of factor VIII, factor VIII/vWF, and factor IX concentrates, respectively. Notably, statistics from the Centers for Disease Control and Prevention (CDC) in August 2022 reported 3.7 cases of hemophilia B and 12 cases of hemophilia A per 100,000 American males in the United States, with 1 in 5,617 male births affected by hemophilia B and 1 in 19,283 male births affected by hemophilia A. Thus, the escalating prevalence of hemophilia serves as a driving force behind the expansion of the blood plasma derivatives market.

Prominent entities within the blood plasma derivatives market are strategically engaging in partnerships to gain a competitive advantage. These strategic alliances aim to ensure patients in need have consistent access to crucial plasma-derived medications, addressing the growing demand for immunoglobulins in France and beyond. A noteworthy example occurred in January 2022 when Kedrion S.p.A., an Italy-based biopharmaceutical company specializing in plasma-derived therapies, collaborated with LPB, a UK-based pharmaceutical company specializing in biological medicinal products. Under this partnership, Kedrion will utilize plasma acquired in France by the Etablissement Français du Sang (EFS) to manufacture immunoglobulins in Hungary. These immunoglobulins will supplement the current supply available to hospitals nationwide, complying with and operating under the supervision of French health authorities. This import from LFB in France will contribute to reinforcing the supply chain of crucial immunoglobulins, aiding in meeting the healthcare demands of patients.

In April 2022, Grifols S.A., a Spain-based leader in the production of plasma-derived medicines, successfully acquired Biotest AG for an undisclosed amount. This strategic acquisition positions Grifols to enhance the accessibility of plasma medicines for patients, accelerate and broaden its product portfolio, take ownership of the most extensive private European network of plasma facilities boasting 87 locations, and contribute to revenue growth and profitability expansion. Biotest AG, based in Germany, is recognized for its role as a producer of various human blood plasma-derived concentrates used in intensive care medicines.

Major companies operating in the blood plasma derivatives market include Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Meiji Group, Grifols S.A., Shire Pharmaceuticals Inc., GC Biopharma Corp, Emergent BioSolutions Inc., Shanghai Raas Blood Products Co Ltd., Kedrion S.p.A., Sanquin, Biotest AG, Bio Products Ltd., ADMA Biologics Inc., China Biologic Products Holdings Inc., BioIVT, PlasmaGen BioSciences Pvt. Ltd., Virchow Biotech Private Limited, LFB S.A., Intas Pharmaceuticals Ltd., Octapharma Plasma.

North America was the largest region in the blood plasma derivatives market in 2024. The regions covered in the blood plasma derivatives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood plasma derivatives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Blood plasma derivatives are pharmaceutical products derived from refined proteins found in blood plasma, including clotting factors, albumins, and other proteins. These derivatives play a crucial role in medical treatment by replenishing deficient or absent proteins within the body.

The primary types of blood plasma derivatives include albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Albumin is a key protein present in these derivatives, contributing to the regulation of osmotic pressure in the blood and aiding in the transportation of hormones, metals, and other molecules throughout the body. These derivatives find application in various medical conditions such as hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's disease, and more. They are utilized by diverse end-users, including hospitals, clinics, and other healthcare institutions.

The blood plasma derivatives market research report is one of a series of new reports that provides blood plasma derivatives market statistics, including blood plasma derivatives industry global market size, regional shares, competitors with a blood plasma derivatives market share, detailed blood plasma derivatives market segments, market trends and opportunities, and any further data you may need to thrive in the blood plasma derivatives industry. This blood plasma derivatives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood plasma derivatives market consists of sales of fibrinogen, globulin, sodium, potassium, bicarbonate, and chloride. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.